Respiratory Research · 2015 · 42 citations · 3 references
MedicineClinical SciencesPharmacotherapyClinical PharmacologyPulmonologyRespiratory PharmacotherapyBronchodilator TherapyChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease PharmacotherapyCombination Inhaler TherapyInhalation TherapyObstructive Lung DiseaseChronic Obstructive Pulmonary Disease BronchodilationChronic Obstructive Pulmonary Disease Exacerbation TreatmentChronic Obstructive Pulmonary Disease Maintenance TherapyClinicaltrials.gov RegistrationPulmonary ExacerbationsRandomized Controlled Trial AppraisalRespiratory Disease Therapy
BACKGROUND: New treatments need to be evaluated in real-world clinical practice to account for co-morbidities, adherence and polypharmacy. METHODS: Patients with chronic obstructive pulmonary disease (COPD), ≥ 40 years old, with exacerbation in the previous 3 years are randomised 1:1 to once-daily fluticasone furoate 100 μg/vilanterol 25 μg in a novel dry-powder inhaler versus continuing their existing therapy. The primary endpoint is the mean annual rate of COPD exacerbations; an electronic medical record allows real-time collection and monitoring of endpoint and safety data. CONCLUSIONS: The Salford Lung Study is the world's first pragmatic randomised controlled trial of a pre-licensed medication in COPD. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT01551758.
3
Nicolás Roche, Helen K. Reddel, Richard J. Martin et al. · Annals of the American Thoracic Society · 2014 · 150 citations
Pharmacy, Quality Management, Comparative Effectiveness Research +16